IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v112y2013i3p241-247.html
   My bibliography  Save this article

Multi-tier drugs assessment in a decentralised health care system. The Italian case-study

Author

Listed:
  • Jommi, Claudio
  • Costa, Enrico
  • Michelon, Alessandra
  • Pisacane, Maria
  • Scroccaro, Giovanna

Abstract

To investigate the organisation and decision-making processes of regional and local therapeutic committees in Italy, as a case-study of decentralised health care systems.

Suggested Citation

  • Jommi, Claudio & Costa, Enrico & Michelon, Alessandra & Pisacane, Maria & Scroccaro, Giovanna, 2013. "Multi-tier drugs assessment in a decentralised health care system. The Italian case-study," Health Policy, Elsevier, vol. 112(3), pages 241-247.
    • Handle: RePEc:eee:hepoli:v:112:y:2013:i:3:p:241-247
    DOI: 10.1016/j.healthpol.2013.06.004
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168851013001668
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.healthpol.2013.06.004?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Martin, Douglas K. & Hollenberg, Daniel & MacRae, Sue & Madden, Shannon & Singer, Peter, 2003. "Priority setting in a hospital drug formulary: a qualitative case study and evaluation," Health Policy, Elsevier, vol. 66(3), pages 295-303, December.
    2. Jenkings, K Neil & Barber, Nick, 2004. "What constitutes evidence in hospital new drug decision making?," Social Science & Medicine, Elsevier, vol. 58(9), pages 1757-1766, May.
    3. Pietro Folino-Gallo & Simona Montilla & Mario Bruzzone & Nello Martini, 2008. "Pricing and reimbursement of pharmaceuticals in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 305-310, August.
    4. Carlson, Josh J. & Sullivan, Sean D. & Garrison, Louis P. & Neumann, Peter J. & Veenstra, David L., 2010. "Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers," Health Policy, Elsevier, vol. 96(3), pages 179-190, August.
    5. Hasle-Pham, Elodie & Arnould, Benoit & Spath, Hans-Martin & Follet, Alain & Duru, Gerard & Marquis, Patrick, 2005. "Role of clinical, patient-reported outcome and medico-economic studies in the public hospital drug formulary decision-making process: results of a European survey," Health Policy, Elsevier, vol. 71(2), pages 205-212, February.
    6. Tediosi, Fabrizio & Gabriele, Stefania & Longo, Francesco, 2009. "Governing decentralization in health care under tough budget constraint: What can we learn from the Italian experience?," Health Policy, Elsevier, vol. 90(2-3), pages 303-312, May.
    7. Hans-Martin Späth & Marie Charavel & Magali Morelle & Marie-Odile Carrère, 2003. "A qualitative approach to the use of economic data in the selection of medecines for hospital formularies: a French survey," Post-Print halshs-00335137, HAL.
    8. Williams, Iestyn P. & Bryan, Stirling, 2007. "Cost-effectiveness analysis and formulary decision making in England: Findings from research," Social Science & Medicine, Elsevier, vol. 65(10), pages 2116-2129, November.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Longo, Francesco, 2016. "Lessons from the Italian NHS retrenchment policy," Health Policy, Elsevier, vol. 120(3), pages 306-315.
    2. Claudio Jommi & Carlotta Galeone, 2023. "The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency," PharmacoEconomics - Open, Springer, vol. 7(3), pages 373-381, May.
    3. Patrizio Armeni & Claudio Jommi & Monica Otto, 2016. "The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 963-977, November.
    4. A. Carletto & A. Cicchetti & S. Coretti & V. Moramarco & M. Ruggeri, 2019. "Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals," Eurasian Business Review, Springer;Eurasia Business and Economics Society, vol. 9(1), pages 89-101, March.
    5. Callea, Giuditta & Armeni, Patrizio & Marsilio, Marta & Jommi, Claudio & Tarricone, Rosanna, 2017. "The impact of HTA and procurement practices on the selection and prices of medical devices," Social Science & Medicine, Elsevier, vol. 174(C), pages 89-95.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Eddama, Oya & Coast, Joanna, 2008. "A systematic review of the use of economic evaluation in local decision-making," Health Policy, Elsevier, vol. 86(2-3), pages 129-141, May.
    2. Gregory Merlo & Katie Page & Julie Ratcliffe & Kate Halton & Nicholas Graves, 2015. "Bridging the Gap: Exploring the Barriers to Using Economic Evidence in Healthcare Decision Making and Strategies for Improving Uptake," Applied Health Economics and Health Policy, Springer, vol. 13(3), pages 303-309, June.
    3. Eddama, Oya & Coast, Joanna, 2009. "Use of economic evaluation in local health care decision-making in England: A qualitative investigation," Health Policy, Elsevier, vol. 89(3), pages 261-270, March.
    4. Gregory Merlo & Katie Page & Pauline Zardo & Nicholas Graves, 2019. "Applying an Implementation Framework to the Use of Evidence from Economic Evaluations in Making Healthcare Decisions," Applied Health Economics and Health Policy, Springer, vol. 17(4), pages 533-543, August.
    5. Armstrong, Kristy & Mitton, Craig & Carleton, Bruce & Shoveller, Jean, 2008. "Drug formulary decision-making in two regional health authorities in British Columbia, Canada," Health Policy, Elsevier, vol. 88(2-3), pages 308-316, December.
    6. Vuorenkoski, Lauri & Toiviainen, Hanna & Hemminki, Elina, 2008. "Decision-making in priority setting for medicines--A review of empirical studies," Health Policy, Elsevier, vol. 86(1), pages 1-9, April.
    7. Williams, Iestyn & Bryan, Stirling, 2007. "Understanding the limited impact of economic evaluation in health care resource allocation: A conceptual framework," Health Policy, Elsevier, vol. 80(1), pages 135-143, January.
    8. Hodgetts, Katherine & Elshaug, Adam G. & Hiller, Janet E., 2012. "What counts and how to count it: Physicians’ constructions of evidence in a disinvestment context," Social Science & Medicine, Elsevier, vol. 75(12), pages 2191-2199.
    9. Williams, Iestyn P. & Bryan, Stirling, 2007. "Cost-effectiveness analysis and formulary decision making in England: Findings from research," Social Science & Medicine, Elsevier, vol. 65(10), pages 2116-2129, November.
    10. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    11. Miller, Fiona A. & Lehoux, Pascale & Rac, Valeria E. & Bytautas, Jessica P. & Krahn, Murray & Peacock, Stuart, 2020. "Modes of coordination for health technology adoption: Health Technology Assessment agencies and Group Procurement Organizations in a polycentric regulatory regime," Social Science & Medicine, Elsevier, vol. 265(C).
    12. Federico Revelli, 2012. "Business taxation and economic performance in hierarchical government structures," Working Papers 2012/12, Institut d'Economia de Barcelona (IEB).
    13. Sofaer, Neema & Kapiriri, Lydia & Atuyambe, Lynn M. & Otolok-Tanga, Erasmus & Norheim, Ole Frithjof, 2009. "Is the selection of patients for anti-retroviral treatment in Uganda fair?: A qualitative study," Health Policy, Elsevier, vol. 91(1), pages 33-42, June.
    14. Bhardwaj, Ramesh, 2015. "Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value," MPRA Paper 63405, University Library of Munich, Germany.
    15. Salome A. Bukachi & Washington Onyango-Ouma & Jared Maaka Siso & Isaac K. Nyamongo & Joseph K. Mutai & Anna Karin Hurtig & Øystein Evjen Olsen & Jens Byskov, 2014. "Healthcare priority setting in Kenya: a gap analysis applying the accountability for reasonableness framework," International Journal of Health Planning and Management, Wiley Blackwell, vol. 29(4), pages 342-361, October.
    16. Coast, Joanna, 2018. "A history that goes hand in hand: Reflections on the development of health economics and the role played by Social Science & Medicine, 1967–2017," Social Science & Medicine, Elsevier, vol. 196(C), pages 227-232.
    17. W. Dominika Wranik & Liesl Gambold & Natasha Hanson & Adrian Levy, 2017. "The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?," International Journal of Health Planning and Management, Wiley Blackwell, vol. 32(2), pages 232-260, April.
    18. Signorelli, C. & Odone, A. & Oradini-Alacreu, A. & Pelissero, G., 2020. "Universal Health Coverage in Italy: lights and shades of the Italian National Health Service which celebrated its 40th anniversary," Health Policy, Elsevier, vol. 124(1), pages 69-74.
    19. Mark Kattenberg & Wouter Vermeulen, 2016. "The Stimulative Effect of an Unconditional Block Grant on the Decentralized Provision of Care," SERC Discussion Papers 0209, Centre for Economic Performance, LSE.
    20. Pirrotta, L. & Guidotti, E. & Tramontani, C. & Bignardelli, E. & Venturi, G. & De Rosis, S., 2022. "COVID-19 vaccinations: An overview of the Italian national health system's online communication from a citizen perspective," Health Policy, Elsevier, vol. 126(10), pages 970-979.

    More about this item

    Keywords

    Drugs; Formulary; Italy; Regions; Assessment;
    All these keywords.

    JEL classification:

    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
    • I14 - Health, Education, and Welfare - - Health - - - Health and Inequality

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:112:y:2013:i:3:p:241-247. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.